Nutriband Inc (NTRB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.97+6.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NTRB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 173.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -33.5% |
Growth built into the price is above our model estimate.
The price assumes 207.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers
Why it matters: Management expects peak US sales for the fentanyl patch to be $80 million to $200 million. Confirmation would show strong market potential.
Supportive ifManagement confirms peak sales numbers during the next earnings call.
Worry ifManagement cuts peak sales numbers a lot.
Why it matters: How the company uses its credit line shows its financial health.
Watch forManagement reports using at least 50% of the $5 million credit line.
Also watch forManagement states that less than 25% of the credit line has been utilized.
Why it matters: Submitting the brand name for FDA approval is a key step for commercialization. It shows progress in bringing the product to market.
Supportive ifA public announcement confirming the FDA submission of the brand name for the fentanyl patch.
Worry ifNo announcement or delay in the FDA submission process.
Why it matters: Using a lot of the credit line may show bigger financial problems and affect operations.
Worry ifCompany draws down more than $2 million from the $5 million credit line.
Less concerning ifCredit line use stays under $2 million. This shows better management of cash.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$254 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $631 loss on $10,000 · 6.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,694 loss on $10,000 · 66.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Revenue from this product is key to achieving management's sales targets. It shows if commercialization is on track.
Supportive ifQ3 revenue from the fentanyl transdermal system is over $1 million.
Worry ifQ3 revenue from the fentanyl transdermal system is below $500,000.
Why it matters: Updates on the credit line will show how well the company manages its financial health. It is important for ongoing operations.
Watch forThere is news of more financing secured. This includes better terms on the credit line.
Also watch forThere are reports of trouble accessing the credit line. Borrowing costs may also be rising.
Why it matters: Nutriband's use of its credit line impacts its money and operations.
Watch forNutriband shares good news about using its $5 million credit line.
Also watch forNutriband says it has problems using the credit line well.
Why it matters: Sales updates for the fentanyl patch show market potential. They also build investor trust.
Supportive ifManagement expects peak annual US sales for the fentanyl patch to be $80 million to $200 million.
Worry ifSales guidance is lower or stays the same, even with market changes.
Why it matters: If revenue growth speeds up, it could mean good news for Nutriband.
Supportive ifHealthcare sector revenue growth moves back toward its highs, above 9%.
Worry ifHealthcare sector revenue growth is slowing down and is now below 9%.
Why it matters: The company secured a $5 million credit line. How it uses this funding will impact financial stability.
Watch forCompany shows it uses the credit line well without raising debt.
Also watch forCompany reports negative cash flow or cannot use the credit line well.
Why it matters: FDA approval is crucial for launching Nutriband's lead product. It can drive future sales.
Supportive ifFDA approves the fentanyl patch that helps prevent abuse.
Worry ifFDA either denies approval or takes a long time to review.
Why it matters: Revenue growth will show if the commercialization strategy is working. It’s key for investor confidence.
Supportive ifQ3 revenue from fentanyl patch sales exceeds $500K.
Worry ifQ3 revenue from fentanyl patch sales remains below $300K.
Why it matters: Higher operating income shows the company is controlling costs. This means less money is lost.
Supportive ifOperating income improves to less than -$0.5M in Q3.
Worry ifOperating income worsens or remains worse than -$1M in Q3.